SCHEMBL1532499

SCHEMBL1532499

Fc1ccc([C@@H]2NCCO[C@H]2OCCc2cc(C(F)(F)F)cc(C(F)(F)F)c2)cc1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TACR1 P25103 16/20 0.64
TP53 P04637 2/20 0.43
CYP1A2 P05177 2/20 0.43
CYP3A4 P08684 2/20 0.43
CYP2D6 P10635 2/20 0.43
TSHR P16473 2/20 0.43
MEN1 O00255 2/20 0.43
KMT2A Q03164 2/20 0.43
MAPT P10636 1/20 0.43
CYP2C9 P11712 1/20 0.43
CYP2C19 P33261 1/20 0.43
THPO P40225 1/20 0.43
HSD17B10 Q99714 1/20 0.43
GMNN O75496 1/20 0.43
LMNA P02545 1/20 0.43
PMP22 Q01453 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
NPSR1 Q6W5P4 1/20 0.43
SLC6A4 P31645 1/20 0.41
SCN9A Q15858 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1637420 1.00 TACR1 (0.64) TACR1TP53CYP1A2CYP3A4CYP2D6
SCHEMBL9035327 1.00 TACR1 (0.64) TACR1TP53CYP1A2CYP3A4CYP2D6
SCHEMBL7964713 1.00 TACR1 (0.64) TACR1TP53CYP1A2CYP3A4CYP2D6
Hydrochloric Acid SCHEMBL28339135 0.99 TACR1 (0.63) TACR1TP53CYP1A2CYP3A4CYP2D6
SCHEMBL9052518 0.96 TACR1 (0.59) TACR1TP53CYP1A2CYP3A4CYP2D6
SCHEMBL9052513 0.96 TACR1 (0.59) TACR1TP53CYP1A2CYP3A4CYP2D6
SCHEMBL9037266 0.95 TACR1 (0.59) TACR1TP53CYP1A2CYP3A4CYP2D6
SCHEMBL9053585 0.93 TACR1 (0.56) TACR1TP53CYP1A2CYP3A4CYP2D6
SCHEMBL9035174 0.91 TACR1 (0.54) TACR1TP53CYP1A2CYP3A4CYP2D6
SCHEMBL9034870 0.90 TACR1 (0.58) TACR1TP53CYP1A2CYP3A4CYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
JP-4647783-B2 2011-03-09 JP claimed
JP-2002518388-A 2002-06-25 JP claimed
EP-1087966-A1 CHEMICAL SYNTHESIS OF MORPHOLINE DERIVATIVES MERCK SHARP & DOHME LTD. (GB) 2001-04-04 EP claimed
WO-1999065900-A1 CHEMICAL SYNTHESIS OF MORPHOLINE DERIVATIVES MERCK SHARP & DOHME LIMITED (GB) 1999-12-23 WO claimed
CN-114478631-A Preparation of fosaprepitant dimeglumine 江苏慧聚药业股份有限公司 2022-05-13 CN disclosed
CN-114478631-A Preparation of fosaprepitant dimeglumine 江苏慧聚药业股份有限公司 2022-05-13 CN disclosed
CN-110655515-A Preparation method of high-purity aprepitant 江苏海悦康医药科技有限公司 2020-01-07 CN disclosed
WO-2009116081-A2 AN IMPROVED PROCESS FOR THE PREPARATION OF APREPITANT MSN LABORATORIES LIMITED (IN) 2009-09-24 WO disclosed
EP-1124826-A1 PROCESS FOR THE PREPARATION OF 2-(R)-(1- (R)-(3,5-BIS (TRIFLUOROMETHYL) PHENYL)ETHOXY) -4-((5-DIMETHYLAMINOMETHYL) -1,2,3-TRIAZOL -4-YL)METHYL) -3-(S)-(4- FLUOROPHENYL) MORPHOLINE Merck & Co., Inc. (US) 2001-08-22 EP disclosed
WO-2000026215-A1 PROCESS FOR THE PREPARATION OF 2-(R)-(1- (R)-(3,5-BIS (TRIFLUOROMETHYL) PHENYL)ETHOXY) -4-((5-DIMETHYLAMINOMETHYL) -1,2,3-TRIAZOL -4-YL)METHYL) -3-(S)-(4- FLUOROPHENYL) MORPHOLINE MERCK & CO., INC. (US) 2000-05-11 WO disclosed
WO-2000026214-A1 LINEAR PROCESS FOR THE PREPARATION OF A MORPHOLINE COMPOUND MERCK & CO., INC. (US) 2000-05-11 WO disclosed
EP-0994867-A1 POLYMORPHIC FORM OF THE TACHYKININ RECEPTOR ANTAGONIST 2-(R)-(1-(R) -(3,5-BIS(TRIFLUOROMETHYL) PHENYL)ETHOXY)-3-(S)-(4-FLUORO) PHENYL-4-(3-5 (-OXO-1H,4H-1,2,4,-TRIAZOLO) METHYLMORPHOLINE Merck & Co., Inc. (US) 2000-04-26 EP disclosed
WO-1999001444-A1 POLYMORPHIC FORM OF THE TACHYKININ RECEPTOR ANTAGONIST 2-(R)-(1-(R) -(3,5-BIS(TRIFLUOROMETHYL) PHENYL)ETHOXY)-3-(S)-(4-FLUORO) PHENYL-4-(3-5 (-OXO-1H,4H-1,2,4,-TRIAZOLO) METHYLMORPHOLINE MERCK & CO., INC. (US) 1999-01-14 WO disclosed
EP-0861251-A1 MORPHOLINE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS MERCK SHARP & DOHME LTD. (GB) 1998-09-02 EP disclosed
WO-1997018206-A1 MORPHOLINE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS MERCK SHARP & DOHME LIMITED (GB) 1997-05-22 WO disclosed